Legend Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-465.95	-518.25	-446.35	-403.58	-266.37	-101.59	Upgrade
Depreciation & Amortization	-	20.45	18.39	13.92	9.93	5.26	Upgrade
Share-Based Compensation	-	47.68	34.34	20.16	4.76	1.27	Upgrade
Other Operating Activities	169.92	10.66	183.58	169.98	18.39	18.62	Upgrade
Operating Cash Flow	-296.03	-439.47	-210.04	-199.53	-233.29	-76.43	Upgrade
Capital Expenditures	-27.17	-20.93	-42.19	0	-26.25	-26.7	Upgrade
Acquisitions	-	-14.81	-1.71	0	-19.49	38.13	Upgrade
Change in Investments	-	-40.01	-147.88	0	25.61	-69.55	Upgrade
Other Investing Activities	-464	-1.35	-3.21	-	-4.03	-0.53	Upgrade
Investing Cash Flow	-491.17	-77.09	-194.98	0	-24.17	-58.65	Upgrade
Share Issuance / Repurchase	-	380.57	628.08	0	463.55	0	Upgrade
Debt Issued / Paid	-	-2.6	-1.42	0	-2.61	14.67	Upgrade
Other Financing Activities	379.09	-	-	-	157.94	-	Upgrade
Financing Cash Flow	379.09	377.98	626.66	0	618.88	14.67	Upgrade
Exchange Rate Effect	2.91	0.68	-2.51	0.03	0.62	0.25	Upgrade
Net Cash Flow	234.61	491	99.6	233.22	371.71	-127.05	Upgrade
Free Cash Flow	-323.2	-460.39	-252.24	-199.53	-259.54	-103.13	Upgrade
Free Cash Flow Margin	-94.28%	-161.46%	-215.58%	-289.91%	-346.06%	-171.95%	Upgrade
Free Cash Flow Per Share	-1.78	-2.62	-1.59	-1.42	-2.20	-1.03	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).